Skip to main content

Table 3 Association between ZOL 5 mg and presence of incident VFs evaluated by a logistic regression analysis

From: Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis

Parameter

Presence of incident VFs

OR

95%CI

p

Administration of ZOL 5 mg

2.10

0.37–11.9

0.4033

Adjusted for age

2.19

0.37–12.9

0.3683

Adjusted for age, BMI

4.49

0.56–36.2

0.1279

Adjusted for age, BMI, ∆ LS-BMD

0.66

0.04–11.3

0.7774

  1. BMD bone mineral density, BMI body mass index, CI confidence interval, LS lumbar spine, VFs vertebral fractures, ∆ percent changes
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us